UNSPSC 51141518: Levetiracetam

This classification denotes a neuroprotective agent and anticonvulsant agent with the molecular formula C8H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44YRR34555, chemically known as 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-, (s)- but generally known as levetiracetam, which bears US NIH Compound Identifier 59708. European Medicines Agency schedules Levetiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08459MIG.

UNSPSC 51141518 Levetiracetam, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally describes a specific anticonvulsant pharmaceutical, but the single recent opportunity posted under it—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and safe drug deactivation systems for community health initiatives, not levetiracetam. This tagging error suggests the code sees little or no genuine activity in state and local markets for the pharmaceutical it is intended to cover.

Seminole County released the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with a one-year renewal option, and vendors must comply with E-Verify, drug-free workplace certification, and federal compliance requirements tied to potential FEMA funding. Given the code's apparent misapplication in the only recent opportunity surfaced, state and local procurement of levetiracetam itself remains unconfirmed in available records.